FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220761617> ?p ?o ?g. }

• W4220761617 abstract "Idiopathic pulmonary fibrosis is a lethal disease driven by myofibroblast expansion. Currently no therapies exist that target the epigenetic mechanisms controlling myofibroblast transdifferentiation, which is responsible for unregulated extracellular matrix (ECM) production. We have recently shown that bromodomain-containing protein 4 (BRD4), an epigenetic regulator that forms a scaffold for nuclear activators and transcription factors, is essential for TGFβ-induced myofibroblast transdifferentiation. However, its role in the development and progression of pulmonary fibrosis in vivo has not been established. Here, we evaluate the hypothesis that BRD4 bromodomain interactions mediate myofibroblast expansion and fibrosing disease in vivo. C57BL/6J mice challenged with intratracheal bleomycin were systemically treated with a selective allosteric inhibitor of the BRD4 bromodomain 1 (BD1), ZL0591 (10 mg/kg), during the established fibrotic phase (14 days post-bleomycin) in a rigorous therapeutic paradigm. Eleven days after initiation of ZL0591 treatment (25 days post-bleomycin), we detected a significant improvement in blood O2 saturation compared to bleomycin/vehicle control. Twenty-eight days post-bleomycin, we observed a reduction in the volumetric Hounsfield Unit (HU) density by micro computed tomography (μCT) in the ZL0591-treated group, as well as a reduction in collagen deposition (hydroxyproline content) and severity of injury (Ashcroft scoring). Myofibroblast transdifferentiation was measured by smooth muscle α-actin (αSMA) staining, indicating a loss of this cell population in the ZL0591-treated group, and corresponded to reduced transcript levels of myofibroblast-associated extracellular matrix genes, tenascin-C and collagen 1α1. We conclude that BRD4 BD1 interactions are critical for myofibroblast transdifferentiation and fibrotic progression in a mouse model of pulmonary fibrosis." @default.
• W4220761617 created "2022-04-03" @default.
• W4220761617 creator A5004847218 @default.
• W4220761617 creator A5023901418 @default.
• W4220761617 creator A5039267745 @default.
• W4220761617 creator A5048097785 @default.
• W4220761617 creator A5060947617 @default.
• W4220761617 creator A5064842058 @default.
• W4220761617 creator A5073875714 @default.
• W4220761617 creator A5082020623 @default.
• W4220761617 creator A5089667898 @default.
• W4220761617 date "2022-03-15" @default.
• W4220761617 modified "2023-09-30" @default.
• W4220761617 title "Selective Inhibition of Bromodomain-Containing Protein 4 Reduces Myofibroblast Transdifferentiation and Pulmonary Fibrosis" @default.
• W4220761617 cites W1515908253 @default.
• W4220761617 cites W1879089985 @default.
• W4220761617 cites W1966672647 @default.
• W4220761617 cites W1988665049 @default.
• W4220761617 cites W2001518113 @default.
• W4220761617 cites W2016613783 @default.
• W4220761617 cites W2017789254 @default.
• W4220761617 cites W2018971124 @default.
• W4220761617 cites W2056269088 @default.
• W4220761617 cites W2065977597 @default.
• W4220761617 cites W2085604666 @default.
• W4220761617 cites W2087467372 @default.
• W4220761617 cites W2090050609 @default.
• W4220761617 cites W2096673680 @default.
• W4220761617 cites W2099540110 @default.
• W4220761617 cites W2106836163 @default.
• W4220761617 cites W2115141581 @default.
• W4220761617 cites W2117488044 @default.
• W4220761617 cites W2123901563 @default.
• W4220761617 cites W2125639937 @default.
• W4220761617 cites W2135383413 @default.
• W4220761617 cites W2140870675 @default.
• W4220761617 cites W2159070657 @default.
• W4220761617 cites W2167732604 @default.
• W4220761617 cites W2170701567 @default.
• W4220761617 cites W2290985779 @default.
• W4220761617 cites W2326698965 @default.
• W4220761617 cites W2346509327 @default.
• W4220761617 cites W2437587891 @default.
• W4220761617 cites W2493422757 @default.
• W4220761617 cites W2543492720 @default.
• W4220761617 cites W2558718156 @default.
• W4220761617 cites W2586435603 @default.
• W4220761617 cites W2606883223 @default.
• W4220761617 cites W2610199736 @default.
• W4220761617 cites W2738074773 @default.
• W4220761617 cites W2793047228 @default.
• W4220761617 cites W2795518453 @default.
• W4220761617 cites W2889492422 @default.
• W4220761617 cites W2897508288 @default.
• W4220761617 cites W2900679912 @default.
• W4220761617 cites W2925251455 @default.
• W4220761617 cites W2940403538 @default.
• W4220761617 cites W2987399803 @default.
• W4220761617 cites W3011089475 @default.
• W4220761617 cites W3012730241 @default.
• W4220761617 cites W3014682240 @default.
• W4220761617 cites W3016965350 @default.
• W4220761617 cites W3135164895 @default.
• W4220761617 cites W3161146383 @default.
• W4220761617 cites W3209671756 @default.
• W4220761617 cites W4206573617 @default.
• W4220761617 doi "https://doi.org/10.3389/fmmed.2022.842558" @default.
• W4220761617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35782526" @default.
• W4220761617 hasPublicationYear "2022" @default.
• W4220761617 type Work @default.
• W4220761617 citedByCount "5" @default.
• W4220761617 countsByYear W42207616172022 @default.
• W4220761617 countsByYear W42207616172023 @default.
• W4220761617 crossrefType "journal-article" @default.
• W4220761617 hasAuthorship W4220761617A5004847218 @default.
• W4220761617 hasAuthorship W4220761617A5023901418 @default.
• W4220761617 hasAuthorship W4220761617A5039267745 @default.
• W4220761617 hasAuthorship W4220761617A5048097785 @default.
• W4220761617 hasAuthorship W4220761617A5060947617 @default.
• W4220761617 hasAuthorship W4220761617A5064842058 @default.
• W4220761617 hasAuthorship W4220761617A5073875714 @default.
• W4220761617 hasAuthorship W4220761617A5082020623 @default.
• W4220761617 hasAuthorship W4220761617A5089667898 @default.
• W4220761617 hasBestOaLocation W42207616171 @default.
• W4220761617 hasConcept C142724271 @default.
• W4220761617 hasConcept C185592680 @default.
• W4220761617 hasConcept C189165786 @default.
• W4220761617 hasConcept C207865475 @default.
• W4220761617 hasConcept C2777420927 @default.
• W4220761617 hasConcept C2780559512 @default.
• W4220761617 hasConcept C2781244666 @default.
• W4220761617 hasConcept C28328180 @default.
• W4220761617 hasConcept C502942594 @default.
• W4220761617 hasConcept C60870556 @default.
• W4220761617 hasConcept C71924100 @default.
• W4220761617 hasConcept C86803240 @default.
• W4220761617 hasConcept C95444343 @default.
• W4220761617 hasConceptScore W4220761617C142724271 @default.
• W4220761617 hasConceptScore W4220761617C185592680 @default.
• W4220761617 hasConceptScore W4220761617C189165786 @default.

• next